IOVA · Iovance Biotherapeutics, Inc. · Executive Compensation
$14.57
+0.34 (+2.35%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$4.98B
Shares
452.97M
Volume · Oct 2
1.11M
Avg daily vol (3M)
17.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Wendy Yarno | member of the Board of Directors | Retired | 2026-03-20 |
| Corleen Roche | Chief Financial Officer | Appointed | 2025-08-07 |
| Matthew W. Rosinack | interim Principal Financial Officer and Principal Accounting Officer | Appointed | 2025-07-03 |
| Jean-Marc Bellemin | Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer | Resigned | 2025-07-03 |
| Jean-Marc Bellemin | Chief Financial Officer and principal financial and accounting officer | Resigned | 2025-06-13 |
| Wendy L. Yarno | director | Appointed | 2023-04-24 |